ライフサイエンスコーパス: ankylosing

1 d lymphocyte-dependent colitis, seronegative ankylosing arthritis and enthesitis, conditions stereoty

2 ythematosus (1346+/-1011 pg per milliliter), ankylosing spondylitis (1368+/-1162 pg per milliliter),

3 improved significantly after MR imaging for ankylosing spondylitis (29% vs 80%, P < .001), undiffere

4 ren of women had an even higher incidence of ankylosing spondylitis (7.2 [1.5-34], p=0.013) than did

5 ot disease and valve disease associated with ankylosing spondylitis (AKS).

6 systemic lupus erythematosus (SLE) (n = 10), ankylosing spondylitis (AS) (n = 10), primary Sjogren's

7 Ankylosing spondylitis (AS) affects 0.25-1.0% of the pop

8 s detailing their application in a number of ankylosing spondylitis (AS) and axial spondyloarthritis

9 mography (MDCT) findings of 41 patients with ankylosing spondylitis (AS) and compared them with pulmo

10 e autoimmune inflammatory arthritis disorder ankylosing spondylitis (AS) and with other related spond

11 Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic inflammatory dis

12 ) affects approximately 40% of patients with ankylosing spondylitis (AS) but also affects patients wi

13 nk/ank mouse develops a phenotype similar to ankylosing spondylitis (AS) in humans.

14 tients with MRI-evident sacroiliitis develop ankylosing spondylitis (AS) in the long term and whether

15 Ankylosing spondylitis (AS) is a chronic inflammatory ar

16 Ankylosing spondylitis (AS) is a common and highly famil

17 Ankylosing spondylitis (AS) is a common, highly heritabl

18 We investigated the proposal that ankylosing spondylitis (AS) is associated with unusual E

19 Ankylosing spondylitis (AS) may present with extra-artic

20 The clinical response in ankylosing spondylitis (AS) patients treated with biolog

21 ment of spinal inflammation in patients with ankylosing spondylitis (AS) relies primarily on magnetic

22 udies of the HLA-B27-transgenic rat model of ankylosing spondylitis (AS) suggested that macrophages d

23 A strong association between ERAP1 and ankylosing spondylitis (AS) was recently identified by t

24 7 subtypes associated with susceptibility to ankylosing spondylitis (AS), and those reported not to b

25 HC) tag SNPs from 1,000 independent cases of ankylosing spondylitis (AS), autoimmune thyroid disease

26 s I molecule B27 is strongly associated with ankylosing spondylitis (AS), but the pathogenic role of

27 rated high heritability of susceptibility to ankylosing spondylitis (AS), it is only recently that th

28 ld standard of rheumatologists' diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA),

29 l and peripheral articular manifestations of ankylosing spondylitis (AS), psoriatic arthritis (PsA),

30 endoplasmic reticulum aminopeptidase 1) with ankylosing spondylitis (AS), which is restricted to HLA-

31 l disease with rheumatoid arthritis (RA) and ankylosing spondylitis (AS).

32 lity of life (HRQOL) in patients with active ankylosing spondylitis (AS).

33 pathogenic role in the spondylarthropathy of ankylosing spondylitis (AS).

34 sulfapyridine (SP), in patients with active ankylosing spondylitis (AS).

35 e treatment of osteoporosis in patients with ankylosing spondylitis (AS).

36 ss I molecules due to their association with Ankylosing Spondylitis (AS).

37 hat is necessary to establish a diagnosis of ankylosing spondylitis (AS).

38 graphic damage in patients with longstanding ankylosing spondylitis (AS).

39 ciated with the chronic inflammatory disease Ankylosing Spondylitis (AS); however, the mechanisms und

40 ASsessment of Ankylosing Spondylitis (ASAS) International Working Grou

41 D16S516), multiple sclerosis (D12S1052), and ankylosing spondylitis (D16S516).

42 = 8), juvenile rheumatoid arthritis (n = 3), ankylosing spondylitis (n = 1), and psoriatic spondylart

43 d IL12B regions convincingly associated with ankylosing spondylitis (P < 5 x 10(-8) in the combined d

44 tients with presumed sarcoidosis compared to ankylosing spondylitis (p = 0.0001), behcet's disease (p

45 ts with presumed sarcoidosis with respect to ankylosing spondylitis (p = 0.0001), behcet's disease, (

46 IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasis and spondyloarthropath

47 ges of patients achieving the Assessments in Ankylosing Spondylitis 20% response (ASAS20) at weeks 12

48 Reactive arthritis, sacroiliitis, and ankylosing spondylitis also appear to be increased in th

49 residues 528 and 575/725 is associated with ankylosing spondylitis among HLA-B27-positive individual

50 riteria for PsA, a new composite measure for ankylosing spondylitis and axial SpA, the ASDAS, new mea

51 ndyloarthropathic changes closely resembling ankylosing spondylitis and DISH.

52 dies of various physical therapy programs in ankylosing spondylitis and identify their benefits and p

53 has supported novel roles for these drugs in ankylosing spondylitis and in cancer prevention, accumul

54 ecent studies indicate that the morbidity of ankylosing spondylitis and PsA are considerably higher t

55 Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I re

56 uding rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis, confirms the impor

57 clude rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis.

58 immune-mediated disorders, most notably with ankylosing spondylitis and psoriasis.

59 of the tumor necrosis factor antagonists in ankylosing spondylitis and psoriatic arthritis has gener

60 necrosis factor inhibitors for patients with ankylosing spondylitis and psoriatic arthritis has had a

61 Sulfasalazine is moderately effective for ankylosing spondylitis and psoriatic arthritis, although

62 The greatest experience has accrued in ankylosing spondylitis and psoriatic arthritis.

63 ved functional status and quality of life in ankylosing spondylitis and psoriatic arthritis.

64 als with tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.

65 are effective and safe for the treatment of ankylosing spondylitis and psoriatic arthritis.

66 cells from healthy donors and patients with ankylosing spondylitis and psoriatic arthritis.

67 Ankylosing spondylitis and related spondylarthritides ar

68 ole for HLA-B27 in genetic susceptibility to ankylosing spondylitis and related spondyloarthropathies

69 Patients with juvenile-onset ankylosing spondylitis appear to have poorer functional

70 or rheumatoid arthritis, where patients with ankylosing spondylitis are offered therapy early in the

71 cant reductions in the signs and symptoms of ankylosing spondylitis at week 16.

72 e for relieving the pain of axial disease in ankylosing spondylitis but these findings contradict two

73 me-wide association study in 2,053 unrelated ankylosing spondylitis cases among people of European de

74 replication in an independent cohort of 898 ankylosing spondylitis cases and 1,518 controls.

75 changes in the course of the disease, Stoke Ankylosing spondylitis classification Spinal Score (SASS

76 oth M-CSF and MMP-3 correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) v

77 onset, disease activity assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

78 ondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

79 cal disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

80 Disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).

81 ter disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = 0.002

82 nthesitis (using the PsA-modified Maastricht Ankylosing Spondylitis Enthesitis Score [MASES] index).

83 ose with psoriatic arthritis, and those with ankylosing spondylitis from phase III trials of golimuma

84 al assessments included the BASDAI, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ank

85 ght, VAS scores for entheseal pain, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bat

86 d functional impairment assessed by the Bath Ankylosing Spondylitis Functional Index (BASFI).

87 nal limitations were assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI; score ra

88 etween inflammation and structural damage in ankylosing spondylitis has been an important focus of re

89 Medical therapy of ankylosing spondylitis has improved dramatically with th

90 ive arthritis, but an infectious trigger for ankylosing spondylitis has not yet been established.

91 d for patients with rheumatoid arthritis and ankylosing spondylitis have been reported, and generic q

92 at has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial.

93 x in determining increased susceptibility to ankylosing spondylitis in children.

94 that TNFi slows radiographic progression in ankylosing spondylitis in data from clinical trials may

95 osome regions in human genome, which control ankylosing spondylitis in human patients.

96 irst published clinical account of a case of ankylosing spondylitis in the United States.

97 f Life (ASQoL) instrument, the ASsessment in Ankylosing Spondylitis International Working Group crite

98 Ankylosing spondylitis is a common form of inflammatory

99 Ankylosing spondylitis is a genetically determined and c

100 Ankylosing spondylitis is an inflammatory autoimmune dis

101 Ankylosing spondylitis is associated with increased risk

102 IL-1A association further substantiate that ankylosing spondylitis is determined to a large extent b

103 modified New York criteria, the diagnosis of ankylosing spondylitis is made based on the presence of

104 Nearly half of the susceptibility to ankylosing spondylitis is provided by major histocompati

105 One of the major goals of treatment of ankylosing spondylitis is to prevent or slow the develop

106 autoimmune disease and evidence showed that ankylosing spondylitis may be a microbiome-driven diseas

107 dation of two new genes, IL23R and ARTS1, in ankylosing spondylitis pathogenesis.

108 shown to be differentially abundant between ankylosing spondylitis patients and healthy controls.

109 A recent trial in ankylosing spondylitis patients demonstrated continuous

110 Specifically, the ankylosing spondylitis patients demonstrated increases i

111 monly used in probiotics, accumulated in the ankylosing spondylitis patients.

112 emic sclerosis patients and in 3 of 12 (25%) ankylosing spondylitis patients.

113 ng Spondylitis Functional Index (BASFI), the Ankylosing Spondylitis Quality of Life (ASQoL) instrumen

114 the Short Form 36 (SF-36) Health Survey and Ankylosing Spondylitis Quality of Life (ASQoL) Questionn

115 tis Disease Activity Index (BASDAI), and the Ankylosing Spondylitis Quality of Life (ASQoL) questionn

116 lvis, and hips were scored by using the Bath Ankylosing Spondylitis Radiology Index (BASRI) by an exp

117 pinal radiographs were scored using the Bath Ankylosing Spondylitis Radiology Index for the spine (BA

118 dy reports four genetic loci associated with ankylosing spondylitis risk and identifies a major role

119 before HLA class I presentation, only affect ankylosing spondylitis risk in HLA-B27-positive individu

120 ) a random sample of members of the National Ankylosing Spondylitis Society.

121 bar spine, which were scored using the Stoke Ankylosing Spondylitis Spine Score.

122 of the interleukin-1 (IL-1) region genes in ankylosing spondylitis suggested the susceptibility to b

123 A recent meta-analysis of published scans of ankylosing spondylitis susceptibility has confirmed site

124 on-major histocompatibility complex genes in ankylosing spondylitis susceptibility, and suggests area

125 ocompatibility complex), 10q, 16q and 19q in ankylosing spondylitis susceptibility.

126 nt GWAS on multiple sclerosis, psoriasis and ankylosing spondylitis that inclusion of known covariate

127 ide strong evidence that HLA-B27 operates in ankylosing spondylitis through a mechanism involving abe

128 Exercise therapy should remain a mainstay of ankylosing spondylitis treatment complementing medical t

129 durations may result in a paradigm shift for ankylosing spondylitis treatment similar to that undergo

130 Ankylosing spondylitis was more prevalent among children

131 50% and 75% of patients were diagnosed with ankylosing spondylitis were ascertained from a database

132 Forty patients with active, inflammatory ankylosing spondylitis were randomly assigned to receive

133 cantly reduces spinal inflammation in active ankylosing spondylitis when compared to placebo; there w

134 esitis-related arthritis progress to develop ankylosing spondylitis within 10 years after presentatio

135 The spondylarthritides (such as ankylosing spondylitis) are multisystem inflammatory dis

136 e SpA (2 with psoriatic arthritis and 1 with ankylosing spondylitis) were isolated by positive select

137 une hemolytic anemia, pernicious anemia, and ankylosing spondylitis), infectious (pneumonia, hepatiti

138 relationship between the gut microbiome and ankylosing spondylitis, a quantitative metagenomics stud

139 Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis, a randomized controlled study, w

140 patients with systemic lupus erythematosus, ankylosing spondylitis, and hepatic fibrosis.

141 anding inflammation in rheumatoid arthritis, ankylosing spondylitis, and juvenile chronic arthritis.

142 tion may have structure-modifying effects in ankylosing spondylitis, and may thereby alter the diseas

143 immune diseases such as behcet's disease and ankylosing spondylitis, and ocular involvement of infect

144 nvestigated one in detail, a risk allele for ankylosing spondylitis, and provide direct evidence of a

145 py not only in RA but also in Crohn disease, ankylosing spondylitis, and several other chronic inflam

146 lgia rheumatica (PMR), giant cell arteritis, ankylosing spondylitis, and Sjogren's syndrome, and to p

147 e of the spondyloarthritides, including PsA, ankylosing spondylitis, and the broader categories of Sp

148 the disease-modifying role of these drugs in ankylosing spondylitis, and their use in the understudie

149 s, two patients with gout, two patients with ankylosing spondylitis, and two patients with psoriatic

150 This group includes 6 entities: ankylosing spondylitis, arthritis associated with inflam

151 h American sample of two new loci related to ankylosing spondylitis, ARTS1 and IL23R, and confirmatio

152 a prospective study involving patients with ankylosing spondylitis, behcet's disease, presumed sarco

153 eously investigated the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, prim

154 0 patients and 45 controls: alopecia areata, ankylosing spondylitis, dermatomyositis, Graves' disease

155 ce of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, familial Mediterranean fever, an

156 esitis in psoriatic arthritis and uveitis in ankylosing spondylitis, have also been observed.

157 principle has relevance to diseases such as ankylosing spondylitis, in which HLA-B27 and ERAP jointl

158 , rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-infectious uveitis, and mult

159 d arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease us

160 e advances in the pharmacological therapy of ankylosing spondylitis, physical therapy remains an esse

161 carrying of the spinal cord in the course of ankylosing spondylitis, present in MRI include: bone mar

162 n the pathogenesis or development process of ankylosing spondylitis, providing new leads for the deve

163 Group criteria for SpA, without evidence of ankylosing spondylitis, psoriasis, inflammatory bowel di

164 ct in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenil

165 ts and for diseases other than RA, including ankylosing spondylitis, psoriatic arthritis, and polymyo

166 uded in the category of spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive ar

167 ry rheumatic diseases that primarily include ankylosing spondylitis, reactive arthritis, and the arth

168 rheumatological conditions (i.e. psoriasis, ankylosing spondylitis, rheumatoid arthritis, fibromyalg

169 able and effective structure modification in ankylosing spondylitis, the data strongly suggest a bene

170 As in human ankylosing spondylitis, the MHC was the major permissive

171 To identify susceptibility loci for ankylosing spondylitis, we undertook a genome-wide assoc

172 There are few effective treatments for ankylosing spondylitis, which causes substantial morbidi

173 atibility complex genes in predisposition to ankylosing spondylitis, which will be summarized here.

174 and women differ in their susceptibility to ankylosing spondylitis, with about 2.5 men affected for

175 de over 90% of the overall susceptibility to ankylosing spondylitis, with about half of the genetic c

176 with unlike conformations in differentially ankylosing spondylitis-associated subtypes) must not be

177 initiate autoimmune damage in patients with ankylosing spondylitis-associated subtypes.

178 espect to understanding the genetic basis of ankylosing spondylitis.

179 pus erythematosus, rheumatoid arthritis, and ankylosing spondylitis.

180 ists are effective for signs and symptoms of ankylosing spondylitis.

181 s and spinal deformities similar to those in ankylosing spondylitis.

182 en shown to be effective in the treatment of ankylosing spondylitis.

183 dissection of the genetic susceptibility to ankylosing spondylitis.

184 otential role in delaying the progression of ankylosing spondylitis.

185 itis and to attenuate spinal inflammation in ankylosing spondylitis.

186 antagonists can prevent structural damage in ankylosing spondylitis.

187 b were also effective in phase III trials in ankylosing spondylitis.

188 thritis can be asymptomatic, as in classical ankylosing spondylitis.

189 or (p75):Fc fusion protein, in patients with ankylosing spondylitis.

190 , and sustained improvement in patients with ankylosing spondylitis.

191 in Sardinia, seem not to be associated with ankylosing spondylitis.

192 ondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.

193 children or siblings of female patients with ankylosing spondylitis.

194 rials of secukinumab in patients with active ankylosing spondylitis.

195 ording to the modified New York criteria for ankylosing spondylitis.

196 s Crohn's disease, rheumatoid arthritis, and ankylosing spondylitis.

197 e epistatic association of both molecules in ankylosing spondylitis.

198 icrobiome are associated with development of ankylosing spondylitis.

199 orm of axial spondyloarthropathies, which is ankylosing spondylitis.

200 -7.0) for psoriasis, psoriatic arthritis, or ankylosing spondylitis.

201 -B27 subtypes differentially associated with ankylosing spondylitis.

202 inflammatory diseases, notably psoriasis and ankylosing spondylitis.

203 th inflammatory bowel disease, psoriasis and ankylosing spondylitis.

204 f exercise and nonpharmacologic therapies in ankylosing spondylitis.

205 on may be of benefit to select patients with ankylosing spondylitis.

206 psoriatic arthritis, reactive arthritis, or ankylosing spondylitis.

207 rmatomyositis; 16 had scleroderma; eight had ankylosing spondylitis; five had juvenile RA; three had